Skip to main content
SpringerLink
Log in

Neurological Complications of Plasma Cell Disorders

  • Chapter
  • First Online:
Lymphoma and Leukemia of the Nervous System

  • 960 Accesses

Abstract

Plasma cell disorders include monoclonal gammopathies of unknown significance, multiple myeloma, plasmacytoma, Waldenstrom’s macroglobulinemia, and amyloidosis. This group of neoplastic diseases involves proliferation of a single clone of plasma cells, producing a monoclonal immunoglobulin protein or immunoglobulin fragment (M protein) that can be identified as a spike on electrophoresis of serum or urine. Plasma cell disorders are associated with a wide spectrum of neurological complications. The pathophysiology, diagnosis, and management of these neurological complications are the subject of this review.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Dispenzieri A, Kyle RA (2005) Neurological aspects of multiple myeloma and related disorders. Best Pract Res Clin Haematol 18:673–688

    Article  PubMed  CAS  Google Scholar 

  2. Spinazze S, Caraceni A, Schrijvers D (2005) Epidural spinal cord compression. Crit Rev Oncol Hematol 56:397–406

    Article  PubMed  Google Scholar 

  3. Maghfoor I, Perry MC (2000) Malignancy: meningeal myeloma: a case report and review of literature. Hematology 5:47–52

    PubMed  Google Scholar 

  4. Roddie P, Collie D, Johnson P (2000) Myelomatous involvement of the dura mater: a rare complication of multiple myeloma. J Clin Pathol 53:398–399

    Article  PubMed  CAS  Google Scholar 

  5. Savage DG, Mears JG, Balmaceda C et al (2002) Leptomeningeal relapse of multiple myeloma following allogeneic stem cell transplantation. Leuk Res 26:689–692

    Article  PubMed  Google Scholar 

  6. Slager UT, Taylor WF, Opfell RW, Myers A (1979) Leptomeningeal myeloma. Arch Pathol Lab Med 103:680–682

    PubMed  CAS  Google Scholar 

  7. Oyajobi BO (2007) Multiple myeloma/hypercalcemia. Arthritis Res Ther 9(Suppl 1):S4

    Article  PubMed  Google Scholar 

  8. Mehta J, Singhal S (2003) Hyperviscosity syndrome in plasma cell dyscrasias. Semin Thromb Hemost 29:467–471

    Article  PubMed  Google Scholar 

  9. Johnson SA, Oscier DG, Leblond V (2002) Waldenstrom’s macroglobulinaemia. Blood Rev 16:175–184

    Article  PubMed  CAS  Google Scholar 

  10. Preston FE, Cooke KB, Foster ME et al (1978) Myelomatosis and the hyperviscosity syndrome. Br J Haematol 38:517–530

    Article  PubMed  CAS  Google Scholar 

  11. Pruzanski W, Watt JG (1972) Serum viscosity and hyperviscosity syndrome in IgG multiple myeloma. Report on 10 patients and a review of the literature. Ann Intern Med 77:853–860

    PubMed  CAS  Google Scholar 

  12. Adams BD, Baker R, Lopez JA, Spencer S (2009) Myeloproliferative disorders and the hyperviscosity syndrome. Emerg Med Clin North Am 27:459–476

    Article  PubMed  Google Scholar 

  13. Pavy MD, Murphy PL, Virella G (1980) Paraprotein-induced hyperviscosity. A reversible cause of stroke. Postgrad Med 68:109–112

    PubMed  CAS  Google Scholar 

  14. Stone MJ (2009) Waldenstrom’s macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia. Clin Lymphoma Myeloma 9:97–99

    Article  PubMed  Google Scholar 

  15. Bernard A, Rousselie F (1986) Macular manifestations of monoclonal dysgammaglobulinemias. Apropos of 3 cases. J Fr Ophthalmol 9:805–810

    CAS  Google Scholar 

  16. Alatoom A, Elsabrouty R, Willis J et al (2009) Fatal cerebral hemorrhage in a patient with CD19-positive IgM-producing aggressive plasma cell myeloma, hyperviscosity syndrome and cryoglobulinemia. Int J Clin Exp Pathol 2:498–507

    PubMed  Google Scholar 

  17. Chen C, Kouroukis CT, White D et al (2009) Bortezomib in relapsed or refractory Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma 9:74–76

    Article  PubMed  CAS  Google Scholar 

  18. Dimopoulos MA, Gertz MA, Kastritis E et al (2009) Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia. J Clin Oncol 27:120–126

    Article  PubMed  Google Scholar 

  19. Treon SP (2009) How I treat Waldenstrom macroglobulinemia. Blood 114:2375–2385

    Article  PubMed  CAS  Google Scholar 

  20. Bing JN, Fog M, Neel AV (1937) Report of a third case of hyperglobulinemia with affection of the central nervous system on a toxi-infectious basis, and some remarks on the differential diagnosis. Acta Med. Scand 91:409–427

    Article  Google Scholar 

  21. Fintelmann F, Forghani R, Schaefer PW et al (2009) Bing-Neel syndrome revisited. Clin Lymphoma Myeloma 9:104–106

    Article  PubMed  Google Scholar 

  22. Edgar R, Dutcher TF (1961) Histopathology of the Bing-Neel syndrome. Neurology 11:239–245

    PubMed  CAS  Google Scholar 

  23. Grewal JS, Brar PK, Sahijdak WM et al (2009) Bing-Neel syndrome: a case report and systematic review of clinical manifestations, diagnosis, and treatment options. Clin Lymphoma Myeloma 9:462–466

    Article  PubMed  Google Scholar 

  24. Malkani RG, Tallman M, Gottardi-Littell N et al (2009) Bing-Neel syndrome: an illustrative case and a comprehensive review of the published literature. J Neurooncol 96(3):301–312

    Article  PubMed  Google Scholar 

  25. Welch D, Whetsell WO Jr., Weil RJ (2002) Pathologic quiz case. A man with long-standing monoclonal gammopathy and new onset of confusion. Central nervous system involvement by Waldenstrom macroglobulinemia-Bing-Neel syndrome. Arch Pathol Lab Med 126:1243–1244

    PubMed  Google Scholar 

  26. Drappatz J, Akar S, Fisher DC et al (2008) Imaging of Bing-Neel syndrome. Neurology 70:1364

    Article  PubMed  CAS  Google Scholar 

  27. Fassas AB, Ward S, Muwalla F et al (2004) Myeloma of the central nervous system: strong association with unfavorable chromosomal abnormalities and other high-risk disease features. Leuk Lymphoma 45:291–300

    Article  PubMed  Google Scholar 

  28. Nieuwenhuizen L, Biesma DH (2008) Central nervous system myelomatosis: review of the literature. Eur J Haematol 80:1–9

    PubMed  Google Scholar 

  29. Dennis M, Chu P (2000) A case of meningeal myeloma presenting as obstructive hydrocephalus – a therapeutic challenge. Leuk Lymphoma 40:219–220

    Article  PubMed  CAS  Google Scholar 

  30. Pontikoglou C, Fragos C, Kolyvaki E et al (2005) Multiple myeloma involving the central nervous system: a report of two cases with unusual manifestations. Leuk Lymphoma 46:737–741

    Article  PubMed  Google Scholar 

  31. Quach H, Ryan G, Ganju V, Prince HM (2005) Effective treatment of leptomeningeal multiple myeloma with total craniospinal irradiation supported by second allogeneic donor stem cell infusion. Bone Marrow Transplant 35:423–424

    Article  PubMed  CAS  Google Scholar 

  32. Veinstein A, Brizard A, Randriamalala E et al (1997) Central nervous system relapses after autologous stem cell transplantation for myeloma. Report of two cases. Hematol Cell Ther 39:327–330

    Article  PubMed  CAS  Google Scholar 

  33. Hogan MC, Lee A, Solberg LA, Thome SD (2002) Unusual presentation of multiple myeloma with unilateral visual loss and numb chin syndrome in a young adult. Am J Hematol 70:55–59

    Article  PubMed  Google Scholar 

  34. Knapp AJ, Gartner S, Henkind P (1987) Multiple myeloma and its ocular manifestations. Surv Ophthalmol 31:343–351

    Article  PubMed  CAS  Google Scholar 

  35. Shone GR (1985) Facial palsy due to myeloma of the temporal bone. J Laryngol Otol 99:907–908

    Article  PubMed  CAS  Google Scholar 

  36. Witt C, Borges AC, Klein K, Neumann HJ (1997) Radiographic manifestations of multiple myeloma in the mandible: a retrospective study of 77 patients. J Oral Maxillofac Surg 55:450–453; discussion 454–455

    Article  PubMed  CAS  Google Scholar 

  37. Colak A, Cataltepe O, Ozgen T, Erbengi A (1989) Spinal cord compression caused by plasmacytomas. A retrospective review of 14 cases. Neurosurg Rev 12:305–308

    Article  PubMed  CAS  Google Scholar 

  38. Spiess JL, Adelstein DJ, Hines JD (1988) Multiple myeloma presenting with spinal cord compression. Oncology 45:88–92

    Article  PubMed  CAS  Google Scholar 

  39. Schiff D (2003) Spinal cord compression. Neurol Clin 21:67–86

    Article  PubMed  Google Scholar 

  40. Young RF, Post EM, King GA (1980) Treatment of spinal epidural metastases. Randomized prospective comparison of laminectomy and radiotherapy. J Neurosurg 53:741–748

    Article  PubMed  CAS  Google Scholar 

  41. Patchell RA, Tibbs PA, Regine WF et al (2005) Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 366:643–648

    Article  PubMed  Google Scholar 

  42. Witham TF, Khavkin YA, Gallia GL et al (2006) Surgery insight: current management of epidural spinal cord compression from metastatic spine disease. Nat Clin Pract Neurol 2:87–94; quiz 116

    Article  PubMed  Google Scholar 

  43. Sun H, Nemecek AN (2009) Optimal management of malignant epidural spinal cord compression. Emerg Med Clin North Am 27:195–208

    Article  PubMed  Google Scholar 

  44. Costa L, Major PP (2009) Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6:163–174

    Article  PubMed  CAS  Google Scholar 

  45. Kyle RA, Gertz MA, Witzig TE et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21–33

    Article  PubMed  Google Scholar 

  46. Mundy GR (1998) Myeloma bone disease. Eur J Cancer 34:246–251

    Article  PubMed  CAS  Google Scholar 

  47. Riggs JE (2002) Neurologic manifestations of electrolyte disturbances. Neurol Clin 20:227–239

    Article  PubMed  Google Scholar 

  48. Nobile-Orazio E, Barbieri S, Baldini L et al (1992) Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies. Acta Neurol Scand 85:383–390

    Article  PubMed  CAS  Google Scholar 

  49. Vrethem M, Cruz M, Wen-Xin H et al (1993) Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies. J Neurol Sci 114:193–199

    Article  PubMed  CAS  Google Scholar 

  50. Silverstein A, Doniger DE (1963) Neurologic complications of myelomatosis. Arch Neurol 9:534–544

    PubMed  CAS  Google Scholar 

  51. Walsh JC (1971) The neuropathy of multiple myeloma. An electrophysiological and histological study. Arch Neurol 25:404–414

    PubMed  CAS  Google Scholar 

  52. Richardson PG, Xie W, Mitsiades C et al (2009) Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 27:3518–3525

    Article  PubMed  CAS  Google Scholar 

  53. Kelly JJ Jr., Kyle RA, O‘Brien PC, Dyck PJ (1981) Prevalence of monoclonal protein in peripheral neuropathy. Neurology 31:1480–1483

    PubMed  Google Scholar 

  54. Ramchandren S, Lewis RA (2009) Monoclonal gammopathy and neuropathy. Curr Opin Neurol 22:480–485

    Article  PubMed  Google Scholar 

  55. Latov N, Braun PE, Gross RB et al (1981) Plasma cell dyscrasia and peripheral neuropathy: identification of the myelin antigens that react with human paraproteins. Proc Natl Acad Sci USA 78:7139–7142

    Article  PubMed  CAS  Google Scholar 

  56. Latov N, Hays AP, Sherman WH (1988) Peripheral neuropathy and anti-MAG antibodies. Crit Rev Neurobiol 3:301–332

    PubMed  CAS  Google Scholar 

  57. Ellie E, Vital A, Steck A et al (1996) Neuropathy associated with “benign” anti-myelin-associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases. J Neurol 243:34–43

    Article  PubMed  CAS  Google Scholar 

  58. Yeung KB, Thomas PK, King RH et al (1991) The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings. J Neurol 238:383–391

    Article  PubMed  CAS  Google Scholar 

  59. Drappatz J, Batchelor T (2004) Neurologic complications of plasma cell disorders. Clin Lymphoma 5:163–171

    Article  PubMed  Google Scholar 

  60. Eurelings M, Moons KG, Notermans NC et al (2001) Neuropathy and IgM M-proteins: prognostic value of antibodies to MAG, SGPG, and sulfatide. Neurology 56:228–233

    PubMed  CAS  Google Scholar 

  61. Nobile-Orazio E, Carpo M (2001) Neuropathy and monoclonal gammopathy. Curr Opin Neurol 14:615–620

    Article  PubMed  CAS  Google Scholar 

  62. Zivkovic SA, Lacomis D, Lentzsch S (2009) Paraproteinemic neuropathy. Leuk Lymphoma 50:1422–1433

    Article  PubMed  CAS  Google Scholar 

  63. Lunn MP, Nobile-Orazio E (2003) Immunotherapy for IgM anti-Myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 1:CD002827

    PubMed  Google Scholar 

  64. Pestronk A, Florence J, Miller T et al (2003) Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 74:485–489

    Article  PubMed  CAS  Google Scholar 

  65. Dalakas MC, Rakocevic G, Salajegheh M et al (2009) Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 65:286–293

    Article  PubMed  CAS  Google Scholar 

  66. Vrethem M, Reiser N, Lauermann C, Svanborg E (2009) Polyneuropathy associated with IgM vs IgG monoclonal gammopathy: comparison between clinical and electrophysiological findings. Acta Neurol Scand 122(1):52–57

    Article  PubMed  Google Scholar 

  67. Gorson KC, Ropper AH, Weinberg DH, Weinstein R (2002) Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy. Arch Neurol 59:766–772

    Article  PubMed  Google Scholar 

  68. Wicklund MP, Kissel JT (2001) Paraproteinemic neuropathy. Curr Treat Options Neurol 3:147–156

    Article  PubMed  Google Scholar 

  69. Hadden RD, Nobile-Orazio E, Sommer C et al (2006) European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 13:809–818

    Article  PubMed  CAS  Google Scholar 

  70. Victor M, Banker BQ, Adams RD (1958) The neuropathy of multiple myeloma. J Neurol Neurosurg Psychiatry 21:73–88

    Article  PubMed  CAS  Google Scholar 

  71. Briemberg HR, Amato AA (2003) Neuromuscular complications of cancer. Neurol Clin 21:141–165

    Article  PubMed  Google Scholar 

  72. Nakanishi T, Sobue I, Toyokura Y et al (1984) The Crow-Fukase syndrome: a study of 102 cases in Japan. Neurology 34:712–720

    PubMed  CAS  Google Scholar 

  73. Kelly JJ Jr., Kyle RA, Miles JM, Dyck PJ (1983) Osteosclerotic myeloma and peripheral neuropathy. Neurology 33:202–210

    PubMed  Google Scholar 

  74. Kuwabara S, Misawa S, Kanai K et al (2008) Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. J Neurol Neurosurg Psychiatry 79:1255–1257

    Article  PubMed  CAS  Google Scholar 

  75. Steck AJ, Czaplinski A, Renaud S (2008) Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: treatment update. Neurotherapeutics 5:528–534

    Article  PubMed  Google Scholar 

  76. Creange A, Chater A, Brouet JC et al (2008) A case of POEMS syndrome treated by autologous hematopoietic stem-cell transplantation. Nat Clin Pract Neurol 4:686–691

    Article  PubMed  Google Scholar 

  77. Gupta S, Rana V, Chandra D et al (2006) Autologous peripheral stem cell transplant for POEMS syndrome: a case report. Hematology 11:361–363

    Article  PubMed  Google Scholar 

  78. Mahdi-Rogers M, Kazmi M, Ferner R et al (2009) Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. J Peripher Nerv Syst 14:118–124

    Article  PubMed  Google Scholar 

  79. Plasmati R, Pastorelli F, Cavo M et al (2007) Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology 69:573–581

    Article  PubMed  CAS  Google Scholar 

  80. Richardson PG, Briemberg H, Jagannath S et al (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113–3120

    Article  PubMed  CAS  Google Scholar 

  81. Julien J, Vital C, Vallat JM et al (1978) Polyneuropathy in Waldenstrom’s macroglobulinemia. Deposition of M component on myelin sheaths. Arch Neurol 35:423–425

    PubMed  CAS  Google Scholar 

  82. Rudnicki SA, Harik SI, Dhodapkar M et al (1998) Nervous system dysfunction in Waldenstrom’s macroglobulinemia: response to treatment. Neurology 51:1210–1213

    PubMed  CAS  Google Scholar 

  83. Vital C, Deminiere C, Bourgouin B et al (1985) Waldenstrom’s macroglobulinemia and peripheral neuropathy: deposition of M-component and kappa light chain in the endoneurium. Neurology 35:603–606

    PubMed  CAS  Google Scholar 

  84. Adams D (2001) Hereditary and acquired amyloid neuropathies. J Neurol 248:647–657

    Article  PubMed  CAS  Google Scholar 

  85. Kyle RA, Greipp PR (1983) Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc 58:665–683

    PubMed  CAS  Google Scholar 

  86. Bloch KJ, Franklin E (1982) Plasma cell dyscrasias and cryoglobulins. JAMA 248:2670–2676

    Article  PubMed  CAS  Google Scholar 

  87. Garcia-Bragado F, Fernandez JM, Navarro C et al (1988) Peripheral neuropathy in essential mixed cryoglobulinemia. Arch Neurol 45:1210–1214

    PubMed  CAS  Google Scholar 

  88. Nemni R, Corbo M, Fazio R et al (1988) Cryoglobulinaemic neuropathy. A clinical, morphological and immunocytochemical study of 8 cases. Brain 111(Pt 3):541–552

    Article  PubMed  Google Scholar 

  89. Vernino S, Wolfe GI (2007) Antibody testing in peripheral neuropathies. Neurol Clin 25:29–46

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Harvard Medical School, Center for Neuro-Oncology, Dana Farber Cancer Institute, Brigham and Women’s Hospital, Boston, MA, 02115, USA

    Jan Drappatz

  2. Departments of Oncology and Neurology, Mayo Clinic Jacksonville, Jacksonville, FL, 32224, USA

    Kurt A. Jaeckle

Authors
  1. Jan Drappatz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kurt A. Jaeckle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan Drappatz .

Editor information

Editors and Affiliations

  1. , Stephen E. and Catherine Pappas Center f, Massachusetts General Hospital, Fruit St. 55, Boston, 02114, Massachusetts, USA

    Tracy Batchelor

  2. Dept. Neurology, Memorial Sloan-Kettering Cancer Center, York Ave. 1275, New York, 10021-6007, New York, USA

    Lisa M. DeAngelis

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Drappatz, J., Jaeckle, K.A. (2012). Neurological Complications of Plasma Cell Disorders. In: Batchelor, T., DeAngelis, L. (eds) Lymphoma and Leukemia of the Nervous System. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-7668-0_18

Download citation

Publish with us

Policies and ethics

Search

Navigation